×
About 60 results

ALLMedicine™ Acute Angioedema Center

Research & Reviews  20 results

Angioedema: differential diagnosis and acute management.
https://doi.org/10.1080/00325481.2021.1945219
Postgraduate Medicine; Tachdjian R, Johnston DT

Jun 18th, 2021 - A clinical vignette illustrates a typical presentation of a patient seeking help for acute angioedema. Despite the risks of SARS-CoV-2 (COVID-19) exposure, it is critical to evaluate patients with acute angioedema in person, because there is alway...

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
https://clinicaltrials.gov/ct2/show/NCT02741596

Jun 8th, 2021 - This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
https://clinicaltrials.gov/ct2/show/NCT02586805

Jun 2nd, 2021 - This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

Pediatric Emergency Department Management of C1 Inhibitor Deficiency.
https://doi.org/10.1097/PEC.0000000000002443
Pediatric Emergency Care; García Sánchez P, Plata Gallardo M et. al.

May 20th, 2021 - C1 inhibitor deficiency is a rare, potentially life-threatening syndrome. Acute attacks of angioedema may occur at any time, so the emergency department (ED) constitutes an indispensable component of its care. To describe the reasons for consultat...

Life-Threatening Acute Angioedema, a Rare Complication After Secondary Blepharoplasty.
https://doi.org/10.1093/asj/sjab093
Aesthetic Surgery Journal; Berenguer B, García T et. al.

Apr 1st, 2021 - Life-Threatening Acute Angioedema, a Rare Complication After Secondary Blepharoplasty.|2021|Berenguer B,García T,San Basilio M,|

see more →

Clinicaltrials.gov  3 results

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
https://clinicaltrials.gov/ct2/show/NCT02741596

Jun 8th, 2021 - This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
https://clinicaltrials.gov/ct2/show/NCT02586805

Jun 2nd, 2021 - This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
https://clinicaltrials.gov/ct2/show/NCT03485911

Mar 2nd, 2021 - This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

see more →

News  1 results

Study Finds Icatibant Relieves Acute Angioedema
https://www.mdedge.com/internalmedicine/article/33680/dermatology/study-finds-icatibant-relieves-acute-angioedema
Sherry Boschert

Apr 8th, 2011 - SAN FRANCISCO – The experimental drug icatibant relieved moderate or severe acute attacks of hereditary angioedema faster than placebo in the third randomized, double-blind, controlled trial of the experimental drug in 98 patients. Among 88 patien.

see more →